Detalles de la búsqueda
1.
American Association of Clinical Endocrinology Consensus Statement: Comprehensive Type 2 Diabetes Management Algorithm - 2023 Update.
Endocr Pract
; 29(5): 305-340, 2023 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-37150579
2.
A new era for oral peptides: SNAC and the development of oral semaglutide for the treatment of type 2 diabetes.
Rev Endocr Metab Disord
; 23(5): 979-994, 2022 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-35838946
3.
American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update.
Endocr Pract
; 28(10): 923-1049, 2022 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-35963508
4.
Insulin glargine 300 units/mL for the treatment of individuals with type 2 diabetes in the real world: A review of the DELIVER programme.
Diabetes Obes Metab
; 23(8): 1713-1721, 2021 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-33881797
5.
Efficacy of liraglutide added to sodium-glucose cotransporter-2 inhibitors in type 2 diabetes, stratified by baseline characteristics: Post-hoc analysis of LIRA-ADD2SGLT2i.
Diabetes Obes Metab
; 23(10): 2234-2241, 2021 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-34132018
6.
Switching to iGlarLixi versus continuation of a daily or weekly glucagon-like peptide-1 receptor agonist (GLP-1 RA) in insufficiently controlled type 2 diabetes: A LixiLan-G trial subgroup analysis by HbA1c and GLP-1 RA use at screening.
Diabetes Obes Metab
; 23(6): 1331-1341, 2021 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-33565209
7.
Insulin glargine 300 U/mL versus first-generation basal insulin analogues in insulin-naïve adults with type 2 diabetes: 12-month outcomes of ACHIEVE Control, a prospective, randomized, pragmatic real-life clinical trial.
Diabetes Obes Metab
; 22(11): 1995-2003, 2020 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-32538550
8.
Insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) compared with premix or addition of meal-time insulin to basal insulin in people with type 2 diabetes: A systematic review and Bayesian network meta-analysis.
Diabetes Obes Metab
; 22(11): 2179-2188, 2020 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-32700442
9.
Efficacy and safety of iGlarLixi versus IDegLira in adults with type 2 diabetes inadequately controlled by glucagon-like peptide-1 receptor agonists: a systematic literature review and indirect treatment comparison.
Diabetes Obes Metab
; 22(11): 2170-2178, 2020 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-32627297
10.
Impact of disease duration and ß-cell reserve on the efficacy of switching to iGlarLixi in adults with type 2 diabetes on glucagon-like peptide-1 receptor agonist therapy: Exploratory analyses from the LixiLan-G trial.
Diabetes Obes Metab
; 22(9): 1567-1576, 2020 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-32323437
11.
Liraglutide as add-on to sodium-glucose co-transporter-2 inhibitors in patients with inadequately controlled type 2 diabetes: LIRA-ADD2SGLT2i, a 26-week, randomized, double-blind, placebo-controlled trial.
Diabetes Obes Metab
; 22(6): 929-937, 2020 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-31984646
12.
Overview of Therapeutic Inertia in Diabetes: Prevalence, Causes, and Consequences.
Diabetes Spectr
; 33(1): 8-15, 2020 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-32116448
13.
Glycaemic goal attainment and hypoglycaemia outcomes in type 2 diabetes patients initiating insulin glargine 300 units/mL or 100 units/mL: Real-world results from the DELIVER Naïve cohort study.
Diabetes Obes Metab
; 21(7): 1596-1605, 2019 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-30843339
14.
Switching to insulin glargine 300 units/mL in real-world older patients with type 2 diabetes (DELIVER 3).
Diabetes Obes Metab
; 21(11): 2384-2393, 2019 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-31264346
15.
Achievement of Target A1C <7.0% (<53 mmol/mol) by U.S. Type 2 Diabetes Patients Treated With Basal Insulin in Both Randomized Controlled Trials and Clinical Practice.
Diabetes Spectr
; 32(2): 93-103, 2019 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-31168279
16.
Long-term sustainability of glycaemic achievements with second-line antidiabetic therapies in patients with type 2 diabetes: A real-world study.
Diabetes Obes Metab
; 20(7): 1722-1731, 2018 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-29536608
17.
Clinical correlates of hypoglycaemia over 4 years in people with type 2 diabetes starting insulin: An analysis from the CREDIT study.
Diabetes Obes Metab
; 20(4): 921-929, 2018 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-29205734
18.
Real-world evidence concerning clinical and economic outcomes of switching to insulin glargine 300 units/mL vs other basal insulins in patients with type 2 diabetes using basal insulin.
Diabetes Obes Metab
; 20(5): 1293-1297, 2018 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-29272064
19.
Clinical outcomes in real-world patients with type 2 diabetes switching from first- to second-generation basal insulin analogues: Comparative effectiveness of insulin glargine 300 units/mL and insulin degludec in the DELIVER D+ cohort study.
Diabetes Obes Metab
; 20(9): 2148-2158, 2018 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-29938887
20.
GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS FOR TYPE 2 DIABETES: A COMPREHENSIVE REVIEW OF HOW TO WEIGH THE OPTIONS, SELECT THE RIGHT PATIENTS, AND MAXIMIZE BENEFITS.
Endocr Pract
; 2018 Aug 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-30084684